Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Named Patient Program data from Korea on teclistamab show ORR 66.7% (28/42), 40.5% CR rate, median PFS 14.1 months (3.1 if R-ISS III), 12-month OS 61.7% with disease progression and infection as most common causes of death.”
Title: Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea
Authors: Jun Ho Yi, Jae Hoon Lee, Sung-Hoon Jung, Ji Hyun Lee, Ji Yun Lee, Kihyun Kim, Sung-Soo Park, Chang-Ki Min, Yoon Seok Choi, Min Kyoung Kim, Ho-Young Yhim, Dok Hyun Yoon
You can read the Full Article on Cancer Research and Treatment.
You can find more posts featuring Robert Orlowski on OncoDaily.
